Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.

ABSTRACT:

Background

ECOG3805 is a randomized trial of testosterone suppression with or without docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). Deeper prostate-specific antigen (PSA) suppression is prognostic for outcome. However, the concordance of PSA rise and radiographic progression has not been examined previously in mHSPC, whereas this has been reported in metastatic castration-resistant prostate cancer.

Objective

To determine the patterns of progression by PSA and radiographic parameters in patients in ECOG3805.

Design, setting, and participants

We conducted a retrospective analysis of all patients in ECOG3805. Patients were classified according to the PSA level at progression (whether PSA level was below 2.0 ng/mL or not) and the type of progression

SUBMITTER: Bryce AH 

PROVIDER: S-EPMC7738423 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature